title: Who should receive extended infusion beta-lactam therapy?
abstract: The increasing prevalence of antibiotic-resistant bacteria challenges a clinician's ability to fight life-threatening infections. Administering beta-lactams via extended infusion may improve patient outcomes. This article discusses the underlying principles of this therapeutic approach and when it may be appropriate.
authors.affiliation: Christopher Roman is an assistant professor in the PA program at Butler University in Indianapolis, Ind. Tia Solh is an academic coordinator and assistant professor in the PA program at Philadelphia College of Osteopathic Medicine in Suwanee, Ga. Kendra M. Damer is an associate professor of pharmacy practice in Butler University's College of Pharmacy and Health Sciences. The authors have disclosed no potential conflicts of interest, financial or otherwise.
authors.forename: Christopher
authors.initials: C
authors.lastname: Roman
authors.forename: Tia
authors.initials: T
authors.lastname: Solh
authors.forename: Kendra M
authors.initials: KM
authors.lastname: Damer
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001424:Bacterial Infections / Q000188:drug therapy*; D015780:Carbapenems / Q000008:administration & dosage; D002511:Cephalosporins / Q000008:administration & dosage; D024881:Drug Resistance, Bacterial; D006801:Humans; D007262:Infusions, Intravenous / Q000706:statistics & numerical data; D018579:Patient Selection; D010406:Penicillins / Q000008:administration & dosage; D047090:beta-Lactams / Q000008:administration & dosage*
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems; D002511:Cephalosporins; D010406:Penicillins; D047090:beta-Lactams